Screening for liver disease in primary care patients across Europe
Studies a care pathway to find people with fatty liver disease early in clinics.
Plain-language title generated from the registry record
Registry title: Global Research Initiative for Patients Screening on MASH
Key facts
- Where
- Antwerp and Brussels, BelgiumSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes, obesity, metabolic syndrome or high blood pressure, to find out who may have fatty liver disease (MASLD or MASH).
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- People with type 2 diabetes, obesity, metabolic syndrome or arterial hypertension, newly diagnosed or already treated, based on the study definitions. No liver disease stage is required.
- Earlier treatment
- People already treated for one of these conditions must have had a prior diagnosis that fits the study definitions. People who had weight-loss (bariatric) surgery in the last 12 months cannot join.
- Biomarker or test result
- The study definitions use test values: for example fasting glucose above 7,0 mmol/L (126 mg/dL), HbA1c of 48 mmol/mol (6.5%) or more, BMI above 30, blood pressure of 140/90 mmHg or more.
Main reasons for not taking part
- Known hepatitis B, hepatitis C, HIV or any other liver condition
- Any other condition that may lead to liver fibrosis or cirrhosis
- Heavy alcohol use: more than 3 units a day for men, more than 2 units a day for women
- Pregnant or breastfeeding
- Weight-loss (bariatric) surgery in the last 12 months
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05651724, who can take part
Where in Belgium
- Antwerp University HospitalAntwerp, BelgiumContact: de JongNo longer taking part
- Hôpital Erasme - Cliniques universitaires de BruxellesBrussels, BelgiumContact: de JongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Julius Clinical
- Trial code
- NCT05651724
- Record updated
- 1 August 2024
- Original description
GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) in primary care centres and clinics in 10 European countries.Read full original descriptionShow less
Global Research Initiative for Patients Screening on MASH - Implementation of an International Transmural Patient Care Pathway
GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) in primary care centres and clinics in 10 European countries.
Inclusion: Newly diagnosed subjects should fulfil criteria for diagnosis of type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension, following the study definitions; Subjects that are currently being treated for type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension, should have had a prior diagnosis based on study definitions; Study definitions:; Type 2 diabetes mellitus; At least 2 times a fasting glucose > 7,0 mmol/L; Or elevated non-fasting glucose >11,1 mmol/L 2 hrs after OGTT; Or HbA1c ≥48 mmol/mol (≥6.5%); Or being actively treated for previously diagnosed type 2 diabetes by a health care provider; Obesity; Body mass index (BMI) > 30; Or waist circumferences Caucasian: male ≥ 94 cm, female ≥ 80 cm South-Asian/Chinese: male ≥90 cm, female ≥80 cm Japanese: male ≥85 cm, female ≥90 cm; Arterial hypertension; Systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg; Or being actively treated for previously diagnosed arterial hypertension by a health care provider; Metabolic syndrome; Central obesity defined as waist circumference (see above), if BMI is >30 kg/m2, central obesity can be assumed and waist circumference does not need to be measured; AND any two of the following:; Raised triglycerides: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality; Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid abnormality; Raised blood pressure (BP): systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or treatment of previously diagnosed hypertension; Raised fasting plasma glucose (FPG): FGP ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes (if above >5.6 mmol/L or 100 mg/dL, an oral glucose tolerance test is strongly recommended, but is not necessary to define presence of the syndrome).
Exclusion: The patient underwent bariatric surgery in the last 12 months; The patient is known with hepatitis B, C or HIV or any other liver condition (like hemochromatosis, sarcoidosis, Wilson's disease etc); The patient is known with any other condition that may lead to liver fibrosis or cirrhosis; The patient has a history or evidence of any other clinically significant condition or planned or expected procedure that in the opinion of the Investigator, may compromise the patient's safety or ability to be included in this study; The patient engages in (excessive) alcohol use: > 3 units/day in males [30 grams/day] and > 2 units/day in females [20 grams/day]; The patient is an employee or contractor of the facility that is conducting the study or is a family member of the Investigator, sub-Investigator, or any Sponsor personnel; The patient is not able to understand the details of the protocol and/or is not able to provide written informed consent; The patient is pregnant or breastfeeding.